Metsera (NASDAQ:MTSR) Raised to "Hold" at Wall Street Zen

Key Points

• Metsera (NASDAQ:MTSR) received an upgrade from a "sell" to a "hold" rating by Wall Street Zen, reflecting a shift in analyst sentiment towards the stock.
• Following the upgrade, Bank of America raised its price target for Metsera from $45 to $50, while Guggenheim increased their price objective from $56 to $62.
• As of now, Metsera holds an average rating of "Moderate Buy" from analysts, with a consensus price target of $55.75.

Metsera (NASDAQ:MTSR - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Wednesday.

Other equities analysts have also issued reports about the company. Leerink Partnrs lowered Metsera from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, September 24th. Bank of America increased their price target on Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a research note on Thursday, August 28th. Guggenheim upped their price objective on Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research report on Tuesday, June 10th. Cantor Fitzgerald restated an "overweight" rating on shares of Metsera in a research report on Wednesday, September 3rd. Finally, Leerink Partners restated a "market perform" rating and set a $57.00 price objective (down from $77.00) on shares of Metsera in a research report on Wednesday, September 24th. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Metsera currently has an average rating of "Moderate Buy" and a consensus price target of $55.75.

Metsera Price Performance

NASDAQ:MTSR opened at $52.33 on Wednesday. The stock has a 50-day simple moving average of $36.95 and a two-hundred day simple moving average of $30.47. Metsera has a 52-week low of $12.30 and a 52-week high of $54.47.

Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings results on Monday, July 28th. The company reported ($0.66) EPS for the quarter.

Institutional Trading of Metsera

A number of institutional investors have recently made changes to their positions in MTSR. Osaic Holdings Inc. boosted its position in shares of Metsera by 45.5% in the 2nd quarter. Osaic Holdings Inc. now owns 946 shares of the company's stock worth $27,000 after purchasing an additional 296 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of Metsera by 100.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,600 shares of the company's stock worth $46,000 after purchasing an additional 800 shares in the last quarter. Strs Ohio acquired a new stake in shares of Metsera in the 1st quarter worth $76,000. Virtus Investment Advisers LLC acquired a new stake in shares of Metsera in the 2nd quarter worth $77,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Metsera in the 2nd quarter worth $122,000.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.